DHL renews IATA CEIV Pharma certification for Singapore operation

This is amidst concerns on losses in the biopharmaceutical sector.

As the world turns the spotlight on the ability of the logistics sector to deliver more than 10 billion doses of COVID-19 vaccines under stringent temperature requirements, DHL Global Forwarding Asia Pacific has renewed the certification of its global stations with IATA CEIV Pharma Standard.

"Singapore is the latest in our Asia Pacific network, along with Japan and China, to receive the IATA CEIV Pharma recertification. This is especially timely as several countries try to secure COVID-19 vaccines to put a halt to the economic and social impact of the pandemic," said Kelvin Leung, CEO of DHL Global Forwarding Asia Pacific.

The certification began in 2016 and will resume its effectiveness for another year. The company said the certification is essential for the international freight company especially now that concerns are growing as the biopharmaceutical sector recorded USD35b loss due to failures in temperature-controlled logistics.

Leung said the accreditation is not only a quality mark of the company’s service and network but also a recognition of the dedication of its specialists who work seamlessly across the world to deliver best-in-class logistics services to the customers.

DHL has been actively involved with IATA's continuous efforts to adequately answer to the regulatory demands of the pharmaceutical industry. At every station, IATA examines and compares the station's correspondence to its Temperature Control Regulations as well as Good Distribution Practices from the European Union, World Health Organisation, and other regulatory bodies.

Moreover, DHL Air GxP (good practice) facility in Singapore has renewed the quality label by exceeding the usual quality standards for transportation and storage of pharmaceutical goods.

"As the freight forwarder that was involved with bringing in Singapore's first batch of Covid-19 vaccines, DHL Global Forwarding places a huge emphasis on delivering the highest supply chain standards for our LSH customers,” said Christopher Lim, managing director at DHL Global Forwarding Singapore and Malaysia.

Lim added the recertification of the IATA CEIV Pharma on a corporate level and for their air freight station at Changi Airport stands testament to their commitment in supporting governments and the LSH sector during crucial recovery periods.

Join Manufacturing Asia community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

The semiconductor giant has job openings for technicians and engineers.
Stakeholders can gain access to insights on current developments in the textile industry.
Its deployment of 3D printing injection mould tools in its production made all the difference.
Electronics manufacturing expanded amidst the global chip shortage.
The company provides direct B2B customization of fabric tech offerings.
Winners will be awarded from the first to the second week of December.
Winners will be recognised via virtual presentations throughout the first and second week of December.
Digital awards presentations will be held in the first and second week of December.
The Singapore Purchasing Manager's Index recorded a two-year high in the latest data, for March 2021.
The brand recently signed a partnership with Seoul-based distributor Sanghyun Yu.
The newly launched radar can provide safety monitoring solutions.
This is amidst concerns on losses in the biopharmaceutical sector.